Wordt geladen...

Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Pharmaceuticals (Basel)
Hoofdauteur: Pardridge, William M.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: MDPI 2020
Onderwerpen:
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7697739/
https://ncbi.nlm.nih.gov/pubmed/33207605
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110394
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!